23 results
8-K
EX-99.1
KRYS
Krystal Biotech Inc
28 Feb 22
Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational Progress
5:11pm
in driving the science and innovation leading to recent positive results from B-VEC, our lead asset from this platform. With this promotion, Suma
8-K
EX-99.2
KRYS
Krystal Biotech Inc
9 Aug 21
Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress
4:02pm
Aesthetics, Inc. Positive pre-clinical data from KB407 for cystic fibrosis demonstrates potential to target lung tissue Continue to drive innovation
8-K
EX-99.2
z7jewh1
1 Jul 21
Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis
5:31pm
8-K
EX-99.1
r0nmri2zecr
7 Jan 21
Regulation FD Disclosure
8:02am
8-K
EX-99.3
jammoqhr
9 Nov 20
Krystal Biotech Reports Third Quarter 2020 Financial Results and Provides Update on Operational Progress
8:32am
424B5
bjkz1c
25 Jun 19
Prospectus supplement for primary offering
4:47pm
424B5
nt2 2489nhwl5wy4q9
24 Jun 19
Prospectus supplement for primary offering
4:34pm
424B5
1th2a6sx7a55 c06og
12 Mar 19
Prospectus supplement for primary offering
9:36am
424B5
532zbk
19 Oct 18
Prospectus supplement for primary offering
5:27pm
424B5
pj6q2jb758vce8jqi
17 Oct 18
Prospectus supplement for primary offering
5:07pm